KKL 顾客使用本产品发表的 2 篇科研文献

ABT-639 is a novel, peripherally acting, selective T-type Ca channel blocker.

ABT-639 blocks recombinant human T-type (Ca_v3.2) Ca channels in a voltage-dependent fashion (IC₅₀=2 μM) and attenuates low voltage-activated (LVA) currents in rat DRG neurons (IC₅₀=8 μM). ABT-639 is significantly less active at other Ca channels (e.g. Ca_v1.2 and Ca_v2.2) (IC₅₀>30 mM). ABT-639 has high oral bioavailability (%F=73), low protein binding (88.9%) and a low brain:plasma ratio (0.05:1) in rodents. Following oral administration ABT-639 produces dose-dependent antinociception in a rat model of knee joint pain (ED₅₀=2 mg/kg, p.o.). ABT-639 (10-100 mg/kg, p.o.) also increases tactile allodynia thresholds in multiple models of neuropathic pain (e.g. spinal nerve ligation, CCI, and vincristine-induced, and capsaicin secondary hypersensitivity). ABT-639 does not attenuate hyperalgesia in inflammatory pain models induced by complete Freund’s adjuvant or carrageenan. At higher doses (e.g. 100-300 mg/kg) ABT-639 does not significantly alter hemodynamic or psychomotor function. The antinociceptive profile of ABT-639 provides novel insights into the role of peripheral T-type (Ca_v3.2) channels in chronic pain states.

Room temperature in continental US; may vary elsewhere.

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。